Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MATTHEW H TAYLOR

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1134239197
CMS profile
277973
Location
PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$69,017.79

58 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
EISAI INC. $27,656.59 27
Blueprint Medicines Corporation $16,623.36 14
E.R. Squibb & Sons, L.L.C. $12,351.67 9
Merck Sharp & Dohme LLC $8,861.17 6
ARRAY BIOPHARMA INC $1,875.00 1
Exelixis Inc. $1,650.00 1

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MATTHEW H TAYLOR

NPI 1134239197 · CMS profile ID 277973

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

PORTLAND, OR

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134239197?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MATTHEW H TAYLOR, NPI 1134239197, CMS profile ID 277973. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134239197?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). MATTHEW H TAYLOR, NPI 1134239197, CMS profile ID 277973. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134239197?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
MATTHEW H TAYLOR, NPI 1134239197, CMS profile ID 277973, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–58 of 58 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1134239197?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

58 matching records · $69,017.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 58 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–58 of 58.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $125.0004/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932852815 CMS
E.R. Squibb & Sons, L.L.C. $186.4104/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932852819 CMS
E.R. Squibb & Sons, L.L.C. $469.4004/26/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932852821 CMS
EISAI INC. $680.0004/01/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908063463 CMS
EISAI INC. $1,020.0003/29/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908063491 CMS
EISAI INC. $1,250.0003/04/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908063467 CMS
Blueprint Medicines Corporation $462.0001/19/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958932971 CMS
ARRAY BIOPHARMA INC $1,875.0001/14/2022 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949354579 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $48,275.16 43
PY2020 $35,261.44 18
PY2021 $64,478.49 43
PY2022 $69,017.79 58
PY2023 $12,819.63 10
PY2024 $855.66 4
PY2025 $44.36 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $4,501,677.21 45
PY2024 Principal investigator $4,596,175.34 46
PY2023 Recipient $4,769.84 2
PY2023 Principal investigator $6,385,340.63 64
PY2022 Principal investigator $3,912,509.61 271
PY2021 Recipient $72.62 1
PY2021 Principal investigator $1,417,023.00 99
PY2020 Recipient $3,518.79 3
PY2020 Principal investigator $2,081,354.85 298
PY2019 Principal investigator $1,936,774.63 358

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

45 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $19,717.88 12/17/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708228
Principal investigator 1 PFIZER INC. $50,440.36 11/26/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708226
Principal investigator 1 Exelixis Inc. $1,555.67 11/17/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377442
Principal investigator 1 PFIZER INC. $589,860.00 11/03/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
ENCORAFENIBBINIMETINIB WITH OR WITHOUT NIVOLUMAB FOR PATIENTS WITH METASTATIC BRAF V600 MUTANT THYROID CANCER No dispute reported 06/30/2026 1228708044
Principal investigator 1 PFIZER INC. $385,823.28 11/03/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
ENCORAFENIBBINIMETINIB WITH OR WITHOUT NIVOLUMAB FOR PATIENTS WITH METASTATIC BRAF V600 MUTANT THYROID CANCER No dispute reported 06/30/2026 1228709069
Principal investigator 1 PFIZER INC. $4,053.48 10/29/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708146
Principal investigator 1 PFIZER INC. $4,175.88 10/25/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708224
Principal investigator 1 PFIZER INC. $7,055.00 10/15/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708144
Principal investigator 1 PFIZER INC. $31,689.00 09/24/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708319
Principal investigator 1 Exelixis Inc. $15,920.68 09/12/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377432
Principal investigator 1 PFIZER INC. $10,087.12 09/10/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708315
Principal investigator 1 Exelixis Inc. $3,879.20 09/03/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377434
Principal investigator 1 Exelixis Inc. $7,758.40 09/03/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377438
Principal investigator 1 Merck Sharp & Dohme LLC $165,517.55 08/18/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A phase II clinical trial evaluating the combination of lenvatinib plus pembrolizumab in patients with treatment naive metastatic uveal melanoma No dispute reported 06/30/2026 1232935643
Principal investigator 1 ModernaTX, Inc. $5,927.72 08/01/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252954313
Principal investigator 1 Exelixis Inc. $1,500.00 07/29/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377436
Principal investigator 1 PFIZER INC. $16,448.52 07/24/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228708888
Principal investigator 1 PFIZER INC. $589,860.00 07/23/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
ENCORAFENIBBINIMETINIB WITH OR WITHOUT NIVOLUMAB FOR PATIENTS WITH METASTATIC BRAF V600 MUTANT THYROID CANCER No dispute reported 06/30/2026 1228709065
Principal investigator 1 PFIZER INC. $385,823.28 07/21/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
ENCORAFENIBBINIMETINIB WITH OR WITHOUT NIVOLUMAB FOR PATIENTS WITH METASTATIC BRAF V600 MUTANT THYROID CANCER No dispute reported 06/30/2026 1228709067
Principal investigator 1 PFIZER INC. $7,295.00 07/02/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709063
Principal investigator 1 PFIZER INC. $91,461.68 07/01/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1AB OPENLABEL MASTER STUDY OF PF07799544 AS A SINGLEAGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 1228709061
Principal investigator 1 PFIZER INC. $6,038.40 06/14/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228708966
Principal investigator 1 Exelixis Inc. $1,365.00 06/13/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377418
Principal investigator 1 Exelixis Inc. $455.00 06/13/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377420
Principal investigator 1 PFIZER INC. $15,728.40 06/05/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228709059
Principal investigator 1 Exelixis Inc. $1,686.40 06/04/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377422
Principal investigator 1 Exelixis Inc. $292.50 06/04/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377424
Principal investigator 1 Exelixis Inc. $6,548.10 06/04/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377426
Principal investigator 1 Exelixis Inc. $1,877.20 06/04/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377430
Principal investigator 1 ModernaTX, Inc. $4,500.00 05/27/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252954307
Principal investigator 1 ModernaTX, Inc. $1,500.00 05/27/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252954309
Principal investigator 1 ModernaTX, Inc. $10,103.40 05/27/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252954317
Principal investigator 1 ModernaTX, Inc. $6,313.95 05/27/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252954321
Principal investigator 1 PFIZER INC. $589,860.00 05/19/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
ENCORAFENIBBINIMETINIB WITH OR WITHOUT NIVOLUMAB FOR PATIENTS WITH METASTATIC BRAF V600 MUTANT THYROID CANCER No dispute reported 06/30/2026 1228708808
Principal investigator 1 PFIZER INC. $385,823.28 05/19/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
ENCORAFENIBBINIMETINIB WITH OR WITHOUT NIVOLUMAB FOR PATIENTS WITH METASTATIC BRAF V600 MUTANT THYROID CANCER No dispute reported 06/30/2026 1228708892
Principal investigator 1 ModernaTX, Inc. $5,051.70 05/01/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252954311
Principal investigator 1 ModernaTX, Inc. $10,610.12 04/22/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252954319
Principal investigator 1 Exelixis Inc. $31,324.54 04/04/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222377428
Principal investigator 1 PFIZER INC. $589,860.00 02/10/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
ENCORAFENIBBINIMETINIB WITH OR WITHOUT NIVOLUMAB FOR PATIENTS WITH METASTATIC BRAF V600 MUTANT THYROID CANCER No dispute reported 06/30/2026 1228708894
Principal investigator 1 PFIZER INC. $385,823.28 02/10/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
ENCORAFENIBBINIMETINIB WITH OR WITHOUT NIVOLUMAB FOR PATIENTS WITH METASTATIC BRAF V600 MUTANT THYROID CANCER No dispute reported 06/30/2026 1228708896
Principal investigator 1 PFIZER INC. $12,241.60 02/05/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A PHASE 1 OPENLABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND ANTI TUMOR ACTIVITY OF PF07799933 ARRY440 AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS No dispute reported 06/30/2026 1228708142
Principal investigator 1 Merck Sharp & Dohme LLC $2,250.00 01/29/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab MK3475 with or without lenvatinib E7080,MK-7902 to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L intervention in a PD-L1 selected populati No dispute reported 06/30/2026 1232917501
Principal investigator 1 Exelixis Inc. $2,396.25 01/21/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase II, Single-Arm Clinical Trial Evaluating the Triplet Combination of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Anti-PD-1(L1) Refractory Cutaneous Melanoma No dispute reported 06/30/2026 1222377408
Principal investigator 1 Exelixis Inc. $13,500.00 01/21/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
A Phase II, Single-Arm Clinical Trial Evaluating the Triplet Combination of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Anti-PD-1(L1) Refractory Cutaneous Melanoma No dispute reported 06/30/2026 1222377410
Principal investigator 1 ModernaTX, Inc. $20,678.39 01/16/2025 Covered Recipient Teaching Hospital
Providence Portland Medical Center
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) No dispute reported 06/30/2026 1252954315